Roasted Coffee | whatsinit

About

What it is and where it shows up.

Roasted coffee is produced by heat-treating green coffee beans (Coffea arabica or Coffea canephora/robusta) at high temperatures (typically 180–240 °C), triggering Maillard reactions that develop the characteristic aroma, flavour, and brown pigmentation. It is consumed globally as a brewed beverage and is widely used as a flavouring agent in foods and beverages.

Safety summary

The regulatory and scientific consensus.

IARC (2016, Monographs Vol. 116) re-classified drinking coffee as Group 3 (not classifiable as carcinogenic to humans) after reviewing over 1,000 studies, and found probable protective associations with liver and uterine endometrial cancer. However, acrylamide—an IARC Group 2A probable carcinogen formed during the Maillard roasting reaction—is present at trace levels; EFSA monitored an average of 221 µg/kg acrylamide in roasted coffee. Caffeine content warrants caution in pregnant women (EFSA recommends ≤200 mg/day total caffeine) and should be avoided in infants and young children; very hot coffee consumption (>65 °C) is classified as IARC Group 2A due to oesophageal cancer risk from thermal injury.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
EFSA (European Food Safety Authority) (European Union)	Approved	EFSA caffeine safety opinion (2015): habitual caffeine intake up to 400 mg/day is safe for non-pregnant adults; single doses up to 200 mg (~3 mg/kg bw for a 70-kg adult) do not raise safety concerns. For pregnant women, total caffeine from all sources should not exceed 200 mg/day. Limit applies to caffeine as a constituent of coffee, not roasted coffee as a whole food.source
FDA (Food and Drug Administration) (United States)	Approved	Coffee was included in FDA's original partial list of GRAS substances submitted during congressional hearings on the Food Additives Amendment (21 CFR); recognised as generally safe for use as a food and beverage ingredient. No specific maximum intake established for the whole ingredient.source

Who should approach with care

Whose guidance would steer them away.

Pregnancy — EFSA recommends pregnant women limit total caffeine intake from all sources to ≤200 mg/day to reduce the risk of fetal growth restriction and adverse birth outcomes.

Lactation — Caffeine passes into breast milk; excessive maternal intake (>200 mg/day) may cause irritability, poor sleep, and elevated heart rate in nursing infants.

Infants — Infants cannot efficiently metabolise caffeine; coffee should not be given to infants due to risk of caffeine accumulation, toxicity, and adverse neurological and cardiovascular effects.

Children — Children are more sensitive to caffeine's stimulant effects and may exceed safe thresholds at relatively low doses; EFSA notes concerns about cardiovascular and neurological effects in this age group.

Heart Disease — Caffeine can transiently elevate heart rate and blood pressure; individuals with arrhythmias, uncontrolled heart disease, or related conditions should seek medical advice regarding safe intake levels.

Research citations

The sources behind this verdict.

1EFSA. Acrylamide in food — EFSA topic page. efsa.europa.eu
2FDA. Enhancing the Regulatory Decision-Making Approval Process for Direct Food Ingredient Technologies — FDA GRAS History (NCBI Bookshelf NBK224037). ncbi.nlm.nih.gov
3PubMed. Production and Inhibition of Acrylamide during Coffee Processing: A Literature Review, 2023. pmc.ncbi.nlm.nih.gov
4PubMed. Comparison of acrylamide and furan concentrations, antioxidant activities, and volatile profiles in cold or hot brew coffees, 2020. pmc.ncbi.nlm.nih.gov
5IARC. Carcinogenicity of drinking coffee, maté, and very hot beverages — IARC Monographs Volume 116, 2016. iarc.who.int
6EFSA. Scientific Opinion on the safety of caffeine (EFSA NDA Panel, 2015), 2015. efsa.europa.eu

Independently researched6 citations